Published in Clin Exp Immunol on June 17, 2011
CD81 and hepatitis C virus (HCV) infection. Viruses (2014) 0.84
Interferon-α improves phosphoantigen-induced Vγ9Vδ2 T-cells interferon-γ production during chronic HCV infection. PLoS One (2012) 0.81
Chronic HCV infection affects the NK cell phenotype in the blood more than in the liver. PLoS One (2014) 0.79
NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines. Cancer Immunol Res (2016) 0.75
NK cell recognition. Annu Rev Immunol (2005) 14.40
The biology of human natural killer-cell subsets. Trends Immunol (2001) 10.10
Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol (2005) 9.00
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol (2006) 3.75
Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev (2006) 3.30
Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med (2002) 2.68
Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology (2009) 2.66
Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology (2006) 2.65
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med (2002) 2.64
Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut (2005) 1.99
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol (2007) 1.86
Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol (2005) 1.62
Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol (2004) 1.59
Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog (2009) 1.56
Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut (2008) 1.47
Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology (2009) 1.40
Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol (1997) 1.38
Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology (2010) 1.37
Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl (2006) 1.29
Variable receptors controlling activation and inhibition of NK cells. Curr Opin Immunol (2002) 1.26
Natural killer cells inhibit hepatitis C virus expression. J Leukoc Biol (2004) 1.21
Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C. J Hepatol (2001) 0.94
Cytokine-activated natural killer cells exert direct killing of hepatoma cells harboring hepatitis C virus replicons. J Interferon Cytokine Res (2006) 0.94
Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells. Eur J Immunol (2006) 0.92
CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection. Clin Exp Immunol (2004) 0.91
Altered innate immunity in chronic hepatitis C infection: cause or effect? Hepatology (2007) 0.90
Increased frequency of CD56Bright NK-cells, CD3-CD16+CD56- NK-cells and activated CD4+T-cells or B-cells in parallel with CD4+CDC25High T-cells control potentially viremia in blood donors with HCV. J Med Virol (2009) 0.87
Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med (2000) 3.26
Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science (1993) 3.06
Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell (1991) 2.83
A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity (1997) 2.45
Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res (1987) 2.22
Differential expression of Ia and Ia-associated invariant chain in mouse tissues after in vivo treatment with IFN-gamma. J Immunol (1986) 1.82
In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol (1993) 1.79
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res (2001) 1.66
The proption of the incorporation of leucine into albumin to that into totaprotein in rat liver and hepatoma Morris 5123 TC. Eur J Biochem (1969) 1.50
Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer. Int J Cancer (1986) 1.48
Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nat Immunol (2000) 1.44
Non-deletional mechanisms of peripheral and central tolerance: studies with transgenic mice with tissue-specific expression of a foreign MHC class I antigen. Immunol Rev (1991) 1.43
Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. Immunity (2000) 1.41
Cell biology of antigen presentation. Curr Opin Immunol (1993) 1.39
Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J Exp Med (1994) 1.36
Distinct mechanisms of extrathymic T cell tolerance due to differential expression of self antigen. Int Immunol (1992) 1.32
Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer (1987) 1.30
Translocation of long peptides by transporters associated with antigen processing (TAP). Eur J Immunol (1996) 1.22
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat (2006) 1.17
The influence of major histocompatibility complex class I antigens on tumor growth and metastasis. Biochim Biophys Acta (1987) 1.17
In vivo induction of H-2K/D antigens by recombinant interferon-gamma. Eur J Immunol (1986) 1.15
Analysis of the fine specificity of rat, mouse and human TAP peptide transporters. Eur J Immunol (1995) 1.13
Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy. Int J Cancer (1987) 1.13
Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood (1987) 1.12
Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class I assembly. J Gen Virol (1996) 1.12
The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. Hepatology (1984) 1.09
Folding and assembly of major histocompatibility complex class I heterodimers in the endoplasmic reticulum of intact cells precedes the binding of peptide. J Exp Med (1993) 1.08
Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur J Immunol (1998) 1.07
The ratio of albumin synthesis to total protein synthesis in normal rat liver, in host liver, and in Morris hepatoma 9121. Cancer Res (1970) 1.06
The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. Eur J Immunol (1997) 1.05
Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res (1991) 1.03
Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology (2000) 1.03
TAP2-defective RMA-S cells present Sendai virus antigen to cytotoxic T lymphocytes. Eur J Immunol (1993) 1.03
Antigen presentation of hen egg-white lysozyme but not of ribonuclease A is augmented by the major histocompatibility complex class II-associated invariant chain. Eur J Immunol (1991) 1.02
Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol (2001) 1.01
Exogenous peptides compete for the presentation of endogenous antigens to major histocompatibility complex class II-restricted T cells. J Exp Med (1991) 1.01
Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur J Immunol (1997) 1.00
Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-Gamma. Int J Cancer (1985) 0.97
Wound complications following kidney and liver transplantation. Clin Transplant (2006) 0.95
A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificity. Eur J Immunol (1996) 0.95
Sequential induction of MHC antigens on autochthonous cells of ileum affected by Crohn's disease. Am J Pathol (1987) 0.94
TAP polymorphism does not influence transport of peptide variants in mice and humans. Eur J Immunol (1995) 0.94
Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res (1996) 0.93
Intracellular distribution of the MHC class II molecules and the associated invariant chain (Ii) in different cell lines. Int Immunol (1993) 0.93
Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens (2000) 0.93
A role for a novel luminal endoplasmic reticulum aminopeptidase in final trimming of 26 S proteasome-generated major histocompatability complex class I antigenic peptides. J Biol Chem (2001) 0.92
Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation. Nephrol Dial Transplant (2007) 0.92
Biliary complications after liver transplantation. Clin Transplant (2006) 0.91
The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant (2006) 0.91
Turnover of autologous alpha 1-antitrypsin in a patient with congenital analbuminemia. Klin Wochenschr (1983) 0.90
Anergy induced by thymic medullary epithelium. Eur J Immunol (1992) 0.90
Bioreactor for a larger scale hepatocyte in vitro perfusion. Transplantation (1994) 0.90
Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor. J Med Virol (2001) 0.90
The rational design of TAP inhibitors using peptide substrate modifications and peptidomimetics. Eur J Immunol (1997) 0.90
Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin. Bone Marrow Transplant (2000) 0.89
Generation, intracellular transport and loading of peptides associated with MHC class I molecules. Curr Opin Immunol (1997) 0.89
Thymic medullary cells expressing B lymphocyte antigens. Hum Pathol (1988) 0.89
Frequency of abnormal expression of HLA-A,B,C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence. Int J Cancer Suppl (1991) 0.88
Extended donor criteria have no negative impact on early outcome after liver transplantation: a single-center multivariate analysis. Transplant Proc (2007) 0.88
Improved hepatocyte in vitro maintenance in a culture model with woven multicompartment capillary systems: electron microscopy studies. Hepatology (1995) 0.88
Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. Cancer Res (1998) 0.87
Resistance to natural killer cell lysis conferred by TAP1/2 genes in human antigen-processing mutant cells. J Immunol (1994) 0.87
Phenotype of stromal cell-associated thymocytes in situ is compatible with selection of the T cell repertoire at an "immature" stage of thymic T cell differentiation. Eur J Immunol (1987) 0.87
Synthesis of angiotensinogen by isolated rat liver cells and its regulation in comparison to serum albumin. Biochem Biophys Res Commun (1977) 0.86
The primary mediastinal clear cell lymphoma of B-cell type has variable defects in MHC antigen expression. Immunology (1986) 0.86
Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain. Eur J Immunol (1995) 0.86
Differential expression of HLA-DR, HLA-DP, HLA-DQ and associated invariant chain (Ii) in normal colorectal mucosa, adenoma and carcinoma. Virchows Arch A Pathol Anat Histopathol (1988) 0.86
Demonstration of sensitized lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis. J Hepatol (1992) 0.85
Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Exp Hematol (1997) 0.85
Reduction or loss of HLA-A,B,C antigens in colorectal carcinoma appears not to influence survival. Br J Cancer (1988) 0.85
Comparison of gastrointestinal loss of alpha-1-antitrypsin and chromium-51-albumin in Ménétrier's disease and the influence of ranitidine. Digestion (1983) 0.85
Presentation of viral antigens restricted by H-2Kb, Db or Kd in proteasome subunit LMP2- and LMP7-deficient cells. Eur J Immunol (1994) 0.85
Growth and metastasis of human tumors in nude mice following tumor-cell inoculation into a vascularized polyurethane sponge matrix. Int J Cancer (1988) 0.84
Fatal varicella in an immunocompromised adult associated with a European genotype E2 variant of varicella zoster virus. J Clin Virol (2008) 0.84
Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast. Virchows Arch A Pathol Anat Histopathol (1989) 0.84
Analbuminemia. Klin Wochenschr (1983) 0.83
Hepatocyte culture between three dimensionally arranged biomatrix-coated independent artificial capillary systems and sinusoidal endothelial cell co-culture compartments. Int J Artif Organs (1994) 0.83
Is a clinical application of hybrid liver support systems limited by an initial disorder in cellular amino acid and alpha-keto acid metabolism, rather than by later gradual loss of primary hepatocyte function? Transplantation (1996) 0.83
Long-term follow-up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease. Hepatology (1984) 0.83
Quasi-elastic light scattering studies of native hepatic bile from the dog: comparison with aggregative behavior of model biliary lipid systems. Biochemistry (1984) 0.82
Ficoll density separation of enzymatically isolated rat liver cells. Acta Hepatogastroenterol (Stuttg) (1974) 0.82
Loss of HLA-A,B,C in colorectal carcinoma is related to the degree of de-differentiation. J Immunogenet (1987) 0.82
[Hemoptysis and acute renal failure in a 29-year-old patient with chronic hepatitis C infection]. Internist (Berl) (2008) 0.81
Lack of vimentin occurring during the intrafollicular stages of B cell development characterizes follicular center cell lymphomas. Blood (1988) 0.81
Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A. Int J Cancer (1999) 0.81
Intra- and extrathymic B cells in physiologic and pathologic conditions. Immunohistochemical study on normal thymus and lymphofollicular hyperplasia of the thymus. Virchows Arch A Pathol Anat Histopathol (1988) 0.81
Hepatitis B virus infection with negative HBV-serology. Lancet (1982) 0.80
Cooperative effect of interferon-gamma and tumor necrosis factor-alpha on the induction of the class II antigen-associated invariant chain expression. Eur J Immunol (1988) 0.80
[Model for end-stage liver disease. New basis of allocation for liver transplantations]. Chirurg (2008) 0.80
Differential effect of transporter Tap 2 gene introduction into RMA-S cells on viral antigen processing. Eur J Immunol (1993) 0.79
Stereoselectivity of in vitro isoprene metabolism. Chem Res Toxicol (1994) 0.79
Secretion of serum albumin by enzymatically isolated rat liver cells. FEBS Lett (1974) 0.79
An early increase in gamma glutamyltranspeptidase and low aspartate aminotransferase peak values are associated with superior outcomes after orthotopic liver transplantation. Transplant Proc (2009) 0.78
Membrane topology and dimerization of the two subunits of the transporter associated with antigen processing reveal a three-domain structure. J Immunol (1999) 0.78
Immunoperoxidase slide assay (IPSA)--a new screening method for hybridoma supernatants directed against cell surface antigens compared to other binding assays. Immunobiology (1983) 0.78
Structural integrity of the human albumin gene in congenital analbuminemia. Biochem Biophys Res Commun (1983) 0.78
[Epithelial membrane markers. Evaluation, presentation of one's own monoclonal antibodies and range of application in histopathology]. Verh Dtsch Ges Pathol (1986) 0.78
Antigen presentation in syrian hamster cells: substrate selectivity of TAP controlled by polymorphic residues in TAP1 and differential requirements for loading of H2 class I molecules. Immunogenetics (1999) 0.78
Is albumin synthesis regulated by the colloid osmotic pressure? Effect of albumin and dextran on albumin and total protein synthesis in isolated rat hepatocytes. Klin Wochenschr (1986) 0.78